Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives

A method of treating a pathology affecting the skin and/or the cutaneous appendages, wherein the pathology affecting the skin and/or the cutaneous appendages is acne, androgenetic alopecia, hirsutism, or seborrheic dermatitis, the method comprising administering to a subject in need thereof an effective amount of a composition comprising

• a) crystalline form III of cortexolone-17α-propionate characterized by a DRX spectrum as represented in FIG. 7, 10, or 13, or a DRX spectrum with at least peaks at about:
• 6.2, 12.6, 14.1, 14.3, 16.0, 22.4, and 23.7 degrees 2theta, or a DSC spectrum as represented in FIG. 8, 11, or 14, or an IR spectrum as shown in FIG. 9, 12, or 15;
• and;
• b) crystalline form IV of cortexolone-17α-propionate characterized by a DRX spectrum as represented in FIG. 28, or a DRX spectrum with at least peaks at about:
• 4.8, 12.9, 14.4, 15.8, 16, 19.3, and 19.5 degrees 2theta.

A method of treating a pathology affecting the skin and/or the cutaneous appendages, wherein the pathology affecting the skin and/or the cutaneous appendages is acne, androgenetic alopecia, hirsutism, or seborrheic dermatitis, the method comprising administering to a subject in need thereof an effective amount of a composition comprising:

• a) water;
• b) at least one physiologically acceptable excipient;
• c) crystalline form III of cortexolone-17α-propionate characterized by a DRX spectrum as represented in FIG. 7, 10, or 13, or a DRX spectrum with at least peaks at about:
• 6.2, 12.6, 14.1, 14.3, 16.0, 22.4, and 23.7 degrees 2theta, or a DSC spectrum as represented in FIG. 8, 11, or 14, or an IR spectrum as shown in FIG. 9, 12, or 15;
• and
• d) crystalline form IV of cortexolone-17α-propionate characterized by a DRX spectrum as represented in FIG. 28, or a DRX spectrum with at least peaks at about:
• 4.8, 12.9, 14.4, 15.8, 16, 19.3, and 19.5 degrees 2theta.